Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241405 | 0.91 | TDP1 (0.59) | PTGDR2TDP1CYP2C9MAPTHPGD | |
| SCHEMBL1853203 | 0.86 | PTGDR2 (0.51) | PTGDR2TDP1CYP2C9MAPT | |
| SCHEMBL1371792 | 0.84 | PTGDR2 (0.68) | PTGDR2TDP1CYP2C9MAPTTSHR | |
| SCHEMBL4574442 | 0.84 | NPC1 (0.56) | PTGDR2TDP1CYP2C9MAPTHPGD | |
| SCHEMBL3951141 | 0.83 | PTGDR2 (0.67) | PTGDR2CYP2C9HPGD | |
| SCHEMBL4145739 | 0.82 | HPGD (0.53) | PTGDR2TDP1CYP2C9MAPTHPGD | |
| SCHEMBL12145499 | 0.82 | PTGDR2 (0.72) | PTGDR2CYP2C9 | |
| SCHEMBL2495570 | 0.81 | ALDH1A1 (0.52) | PTGDR2TDP1CYP2C9HPGDTSHR | |
| SCHEMBL4200563 | 0.81 | ALDH1A1 (0.66) | PTGDR2HPGD | |
| SCHEMBL2947402 | 0.81 | PTGDR2 (0.56) | PTGDR2TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605158-B2 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-20 | — | — | US | disclosed |
| US-7605158-B2 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1812113-A1 | PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS | Argenta Discovery Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1776982-A1 | Pyrimidine compounds as histamine modulators | Argenta Discovery Limited (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| EP-1767537-A1 | Pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006050965-A1 | PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS | ARGENTA DISCOVERY LTD (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | PTGDR2 346/4885TDP1 858/4885CYP2C9 2888/4885 |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | HRH4, HRH3, HRH2 | PTGDR2 628/4885TDP1 1569/4885CYP2C9 3839/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | PTGDR2 2108/4885TDP1 3593/4885CYP2C9 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.